In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Applied DNA Sciences (APDN), with a price target of $3. The company’s shares closed yesterday at $1.05, close to its 52-week low of $1.
Vendetti said:
“Applied DNA Sciences held an analyst webinar highlighting the linear DNA platform of its private subsidiary, LineaRx. The move expands the company’s pipeline into the high-risk but potentially high-reward therapeutic space.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.4% and a 48.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Currently, the analyst consensus on Applied DNA Sciences is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.80 and a one-year low of $1. Currently, Applied DNA Sciences has an average volume of 146.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied DNA Sciences, Inc. engages in the security solutions. It provides biotechnology-driven solutions to help protect products, brands, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
